Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof-of-concept clinical trial of WP-1220 for the treatment of cutaneous T-cell lymphoma (CTCL)

Trial Profile

A proof-of-concept clinical trial of WP-1220 for the treatment of cutaneous T-cell lymphoma (CTCL)

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs WP 1220 (Primary)
  • Indications Cutaneous T-cell lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 Aug 2018 According to a Moleculin Biotech media release, company announced it has submitted a request to Polish authorities for clinical trial authorization (CTA) for its STAT3 inhibitor, WP1220, for the treatment of Cutaneous T-Cell Lymphoma (CTCL).
    • 24 Oct 2017 According to a Moleculin Biotech media release, the company hope to be enrolling patients near year-end.
    • 14 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top